Canada markets closed

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.41-0.56 (-8.03%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close6.97
Open6.79
Bid5.91 x 3100
Ask7.16 x 1400
Day's Range6.14 - 6.83
52 Week Range1.45 - 7.91
Volume126,927
Avg. Volume266,679
Market Cap241.104M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.01
Earnings DateMar 01, 2023 - Mar 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • GlobeNewswire

    Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

    Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemiaFOSTER CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat

  • Simply Wall St.

    We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in second half of 2023IND-enabling activities for TERN-601 (oral GLP-1R agonist) remain on track with plans to initiate first-in-human clinical trial in obesity in 2023Cash and equivalents of $187 million provides runway into 2025, incl